Skip to main content

3 Result(s)

within Eric Raefsky Remove this filter

and

  1. No Access

    Article

    Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial

    Amrubicin is a synthetic anthracycline which has been shown in preclinical studies to have broad-spectrum anti-tumor activity and a lower potential for cardiotoxicity as compared to doxorubicin. We conducted a...

    Denise A. Yardley, Eric Raefsky, John D. Hainsworth… in Breast Cancer Research and Treatment (2014)

  2. No Access

    Article

    A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer

    nab-Paclitaxel has shown favorable efficacy and toxicity profiles compared to other taxanes in the treatment of metastatic breast cancer. In this pilot trial, we evaluated a nab-paclitaxel-containing adjuvant reg...

    Denise Yardley, Howard Burris III, Nancy Peacock… in Breast Cancer Research and Treatment (2010)

  3. No Access

    Article

    Phase I Study of JM-216 (an Oral Platinum Analogue) in Combination with Paclitaxel in Patients with Advanced Malignancies

    This phase I study wasconducted to determine the dose limitingtoxicity, maximum tolerated doses, andrecommended phase II doses of thecombination of JM-216 and paclitaxel. Patients received paclitaxel intraveno...

    Suzanne Jones, John Hainsworth, Howard A. Burris III… in Investigational New Drugs (2002)